AURUM PHARMACEUTICALS LIMITED

Directors' Report and

Unaudited Financial Statements

for the Year Ended 31 December 2018

Company Number: 02581060

AURUM PHARMACEUTICALS LIMITED

Contents of the Financial Statements
for the year ended 31 December 2018

# Company Information
for the year ended 31 December 2018

| | |
|---|---|
| **Directors:** | B Deluard<br>P E Parry<br>E Schmidt |
| **Registered office:** | Bampton Road<br>Harold Hill<br>Romford<br>Essex<br>RM3 8UG |
| **Registered number:** | 02581060 |

AURUM PHARMACEUTICALS LIMITED

## Directors' Report
## for the year ended 31 December 2018

The directors present their report with the financial statements of the company for the year ended 31 December 2018.

**Directors**

P Parry has held office during the whole of the period from 1 January 2018 to the date of this report.

Other changes in directors holding office are as follows:

B Deluard and E Schmidt were appointed as directors on 11 March 2019.

M Harris ceased to be a director on 1 January 2019.

R Joannesse ceased to be a director on 11 March 2019.

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

**On behalf of the board:**

.....................................................................

P E Parry - Director

Date: 25th Sept 2019

AURUM PHARMACEUTICALS LIMITED
(REGISTERED NUMBER: 02581060)

## Balance Sheet
## 31 December 2018

| | Notes | £ | 2018 £ | £ | 2017 £ |
|---|---|---|---|---|---|
| **Current assets** | | | | | |
| Debtors | 3 | 103 | | 103 | |
| **Total assets less current liabilities** | | | 103 | | 103 |
| **Capital and reserves** | | | | | |
| Called up share capital | 4 | | 100 | | 100 |
| Capital redemption reserve | | | 2 | | 2 |
| Retained Earnings | | | 1 | | 1 |
| **Shareholders' funds** | | | 103 | | 103 |

The company is entitled to exemption from audit under section 480 or the Companies Act 2006 for the year ended 31 December 2019.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2019 in accordance with section 476 of the Companies Act 2006.

The directors acknowledge:

a) Ensuring the company keeps accounting records which company with Sections 386 and 387 of the Companies Act 2006 and
b) Preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and its profit of loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to the financial statements, so far as applicable to the company.

The financial statements have been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the Board of Directors on 25th Sept 2019 and were signed on its behalf by:

.......................................................................

P E Parry - Director

## Income Statement
## For the year ended 31 December 2018

During the financial year and the preceding financial year, the company has not traded and has received no income and incurred no expenditure. Consequently, during those periods the company has made neither a surplus nor a deficit.

1. **Statutory information**

Aurum Pharmaceuticals Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. **Accounting policies**

**Basis of preparing the financial statements**
These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

3. **Debtors: amounts falling due within one year**

| | 2018<br>£ | 2017<br>£ |
|---|---|---|
| Amounts due from group undertakings | 103 | 103 |
| | 103 | 103 |

4. **Called up share capital**

**Authorised**

| | 2018<br>£ | 2017<br>£ |
|---|---|---|
| 900 ordinary 'A' shares of £1 each | 900 | 900 |
| 100 ordinary 'B' shares of £1 each | 100 | 100 |
| | 1000 | 1000 |

**Allotted, called up and fully paid**

| | 2018<br>£ | 2017<br>£ |
|---|---|---|
| 100 ordinary 'A' shares of £1 each | 100 | 100 |

The 'A' and 'B' shares rank pair passu in all respects.

5. **Ultimate controlling party.**

The ultimate parent undertaking is Financière Verdi III, a company incorporated in France.

Financière Verdi III prepares group financial statements and copies can be obtained from:

Financière Verdi III
194, Bureaux de la Colline
92213 Saint-Cloud – FRANCE

6. **Contingent liabilities**

The Company has guaranteed bank and other borrowings of a parent undertaking, Orphea Limited, amounting to £55 million (2017: £55 million).